CRISPR BY DESIGN
Dead / Abandoned — Abandoned — no statement of use filed (as of 22 Sept 2025)
What this means for you
This application is over — abandoned 22 Sept 2025. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 90596751
- Mark type
- Stylized text
- Filed
- 23 Mar 2021
- Published for opposition
- 21 Jun 2022
- Abandoned
- 22 Sept 2025
- Attorney of record
- John Paul Oleksiuk
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical and biological preparations based on genetic engineering and gene therapy for use in diagnosis, prevention, and treatment of diseases in human therapeuticsin the nature of diseases caused by genetic mutations or for which gene modification would ameliorate or cure the disease or disorder; Gene therapy products, namely, biological preparations based on engineered cells for medical use for the treatment of diseases caused by genetic mutations or for which gene modification would ameliorate or cure the disease or disorder related to immuno-oncology, degenerative disorders, traumatic injury, enzyme replacement therapy, and immunology; Pharmaceutical and biological preparations based on gene, genome, and cellular editing, modulation, and modification for use in human therapeutics in the nature of diseases caused by genetic mutations or for which gene modification would ameliorate or cure the disease or disorder; Pharmaceutical preparations, namely, therapeutic pharmaceuticals developed through genome modifications for the prevention and treatment of genomic disorders, namely, neurological disorders, Huntington's disease, amyotrophic lateral sclerosis (ALS), front temporal dementia, pain, Alzheimer's, Parkinson's, ataxia, autism, epilepsy, pain, and also cardiovascular, peripheral nervous system, cancer, endocrine, gastrointestinal, renal, genetic immunological, hepatic, infectious, inflammatory, metabolic, autoimmune, musculoskeletal, neurological, ophthalmological, respiratory, urogenital, urological, hematologic and viral or bacterial diseases and disorders
- Class 044 — Medical, beauty and agricultural services: Molecular diagnostic testing, monitoring and reporting services for medical purposes and medical research purposes; Medical diagnostic testing services in the field of human disease and human medical conditions
Owner
- Scribe Therapeutics Inc., Alameda, CA, US
- Scribe Therapeutics Inc., Alameda, CA, US
Prosecution history
- 22 Sept 2025 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 22 Sept 2025 — ABANDONMENT - NO USE STATEMENT FILED
- 29 Jan 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 28 Jan 2025 — SOU EXTENSION 5 GRANTED
- 22 Jan 2025 — SOU EXTENSION 5 FILED
- 22 Jan 2025 — SOU TEAS EXTENSION RECEIVED
- 16 Dec 2024 — CORRECTED NOA E-MAILED
- 16 Dec 2024 — DIVISIONAL PROCESSING COMPLETE
- 19 Aug 2024 — DIVISIONAL REQUEST RECEIVED
- 16 Dec 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 16 Dec 2024 — SOU EXTENSION 4 GRANTED
- 14 Aug 2024 — SOU EXTENSION 4 FILED
- 22 Nov 2024 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 18 Nov 2024 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 23 Oct 2024 — CASE ASSIGNED TO INTENT TO USE PARALEGAL